CONDENSED CONSOLIDATED GUARANTOR FINANCIAL INFORMATION (Details 2) (USD $) In Thousands, unless otherwise specified	1 Months Ended	2 Months Ended	3 Months Ended		4 Months Ended	6 Months Ended
	Apr. 30, 2011	Jun. 30, 2011	Jun. 30, 2012	Mar. 31, 2012	Apr. 30, 2011	Jun. 30, 2012
REVENUE
Product sales, net		$ 35,902	$ 56,523			$ 111,147
Royalty revenue		1,068	4,804			10,722
License fees			11			20
Total Revenue		36,970	61,338			121,889
EXPENSES
Cost of products sold		26,934	27,322			52,006
License and royalty fees		50	63			174
Research and development		2,829	2,423			4,408
Selling, general and administration		12,781	17,784			35,431
Depreciation and amortization		5,690	8,428			17,451
Write-down of property, plant and equipment			692			865
Total Expenses		48,284	56,712			110,335
Operating income (loss)		(11,314)	4,626			11,554
Other income (expense)
Foreign exchange (loss) gain		492	214			(56)
Other (expense) income		112	240			902
Interest expense		(3,032)	(4,306)			(8,558)
Impairments and realized losses on investments			(68)			(349)
Total other expenses		(2,428)	(3,920)			(8,061)
Income (loss) before reorganization items and income taxes		(13,742)	706			3,493
Income (loss) before income tax		(13,742)	706			3,493
Income tax expense (recovery)	(600)	506	3,654		300	6,440
Income (loss) from operations		(14,248)	(2,948)			(2,947)
Net (loss) income		(14,248)	(2,948)	1		(2,947)
Parent Company Angiotech Pharmaceuticals, Inc.
REVENUE
Product sales, net		7
Royalty revenue		94	4,051			9,187
Total Revenue		101	4,051			9,187
EXPENSES
License and royalty fees		50	63			174
Research and development		1,216	389			813
Selling, general and administration		1,730	2,851			5,381
Depreciation and amortization		2,466	3,819			7,795
Write-down of property, plant and equipment			692			692
Total Expenses		5,462	7,814			14,855
Operating income (loss)		(5,361)	(3,763)			(5,668)
Other income (expense)
Foreign exchange (loss) gain		172	123			(11)
Other (expense) income		652	4			596
Interest expense		(2,784)	(4,108)			(8,216)
Impairments and realized losses on investments			(68)			(349)
Total other expenses		(1,960)	(4,049)			(7,980)
Income (loss) before income tax		(7,321)	(7,812)			(13,648)
Income tax expense (recovery)		509	95			(41)
Income (loss) from operations		(7,830)	(7,907)			(13,607)
Equity in subsidiaries		(6,418)	4,959			10,660
Net (loss) income		(14,248)	(2,948)			(2,947)
Guarantor Subsidiaries
REVENUE
Product sales, net		26,341	40,704			79,304
Royalty revenue		974	753			1,535
Total Revenue		27,315	41,457			80,839
EXPENSES
Cost of products sold		18,065	17,080			30,964
Research and development		1,517	1,996			3,455
Selling, general and administration		9,267	12,329			24,851
Depreciation and amortization		2,933	4,367			8,972
Write-down of property, plant and equipment						173
Total Expenses		31,782	35,772			68,415
Operating income (loss)		(4,467)	5,685			12,424
Other income (expense)
Foreign exchange (loss) gain		24	12			(16)
Other (expense) income		(2,696)	236			306
Interest expense		(235)	(198)			(342)
Total other expenses		(2,907)	50			(52)
Income (loss) before income tax		(7,374)	5,735			12,372
Income tax expense (recovery)		(774)	2,449			4,074
Income (loss) from operations		(6,600)	3,286			8,298
Equity in subsidiaries		1,286	3,621			6,536
Net (loss) income		(5,314)	6,907			14,834
Non Guarantor Subsidiaries
REVENUE
Product sales, net		12,284	19,274			38,884
License fees			11			20
Total Revenue		12,284	19,285			38,904
EXPENSES
Cost of products sold		10,446	12,262			25,163
Research and development		96	38			140
Selling, general and administration		1,784	2,604			5,199
Depreciation and amortization		291	242			684
Total Expenses		12,617	15,146			31,186
Operating income (loss)		(333)	4,139			7,718
Other income (expense)
Foreign exchange (loss) gain		296	79			(29)
Other (expense) income		2,156
Interest expense		(13)
Total other expenses		2,439	79			(29)
Income (loss) before income tax		2,106	4,218			7,689
Income tax expense (recovery)		771	1,110			2,407
Income (loss) from operations		1,335	3,108			5,282
Net (loss) income		1,335	3,108			5,282
Consolidating Adjustments
REVENUE
Product sales, net		(2,730)	(3,455)			(7,041)
Total Revenue		(2,730)	(3,455)			(7,041)
EXPENSES
Cost of products sold		(1,577)	(2,020)			(4,121)
Total Expenses		(1,577)	(2,020)			(4,121)
Operating income (loss)		(1,153)	(1,435)			(2,920)
Other income (expense)
Income (loss) before income tax		(1,153)	(1,435)			(2,920)
Income (loss) from operations		(1,153)	(1,435)			(2,920)
Equity in subsidiaries		5,132	(8,580)			(17,196)
Net (loss) income		3,979	(10,015)			(20,116)
Predecessor
REVENUE
Product sales, net	16,365				69,198
Royalty revenue	5,285				10,941
License fees	24				127
Total Revenue	21,674				80,266
EXPENSES
Cost of products sold	8,291				32,219
License and royalty fees					68
Research and development	1,156				5,686
Selling, general and administration	6,191				24,846
Depreciation and amortization	3,088				14,329
Write-down of assets held for sale	570				570
Write-down of property, plant and equipment					215
Total Expenses	19,296				77,933
Operating income (loss)	2,378				2,333
Other income (expense)
Foreign exchange (loss) gain	(366)				(646)
Other (expense) income	10				34
Interest expense	(2,217)				(10,327)
Total other expenses	(2,573)				(10,939)
Income (loss) before reorganization items and income taxes	(195)				(8,606)
Reorganization items	329,826				321,084
Gain on extinguishment of debt and settlement of other liabilities	67,307				67,307
Income (loss) before income tax	396,938				379,785
Income tax expense (recovery)	(581)				267
Income (loss) from operations	397,519				379,518
Net (loss) income	397,519				379,518
Predecessor | Parent Company Angiotech Pharmaceuticals, Inc.
REVENUE
Product sales, net	3				8
Royalty revenue	5,238				9,930
Total Revenue	5,241				9,938
EXPENSES
License and royalty fees					68
Research and development	583				2,448
Selling, general and administration	1,672				3,187
Depreciation and amortization	808				3,007
Write-down of assets held for sale	570				570
Total Expenses	3,633				9,280
Operating income (loss)	1,608				658
Other income (expense)
Foreign exchange (loss) gain	(242)				(492)
Other (expense) income	2				1,116
Interest expense	(1,210)				(7,372)
Total other expenses	(1,450)				(6,748)
Income (loss) before reorganization items and income taxes	158				(6,090)
Reorganization items	89,011				81,377
Gain on extinguishment of debt and settlement of other liabilities	67,307				67,307
Income (loss) before income tax	156,476				142,594
Income tax expense (recovery)	(111)				(197)
Income (loss) from operations	156,587				142,791
Equity in subsidiaries	119				(4,086)
Net (loss) income	156,706				138,705
Predecessor | Guarantor Subsidiaries
REVENUE
Product sales, net	15,222				54,494
Royalty revenue	47				1,011
Total Revenue	15,269				55,505
EXPENSES
Cost of products sold	7,433				22,041
Research and development	522				3,022
Selling, general and administration	3,646				18,198
Depreciation and amortization	2,205				11,021
Write-down of property, plant and equipment					215
Total Expenses	13,806				54,497
Operating income (loss)	1,463				1,008
Other income (expense)
Foreign exchange (loss) gain	42				(46)
Other (expense) income	(5)				(1,134)
Interest expense	(996)				(2,914)
Total other expenses	(959)				(4,094)
Income (loss) before reorganization items and income taxes	504				(3,086)
Reorganization items	216,567				215,409
Income (loss) before income tax	217,071				212,373
Income tax expense (recovery)	(685)				(910)
Income (loss) from operations	217,756				213,383
Equity in subsidiaries	414				2,502
Net (loss) income	218,170				215,785
Predecessor | Non Guarantor Subsidiaries
REVENUE
Product sales, net	5,617				22,832
License fees	24				127
Total Revenue	5,641				22,959
EXPENSES
Cost of products sold	3,387				14,783
Research and development	51				216
Selling, general and administration	873				3,461
Depreciation and amortization	75				301
Total Expenses	4,386				18,761
Operating income (loss)	1,255				4,198
Other income (expense)
Foreign exchange (loss) gain	(166)				(108)
Other (expense) income	13				52
Interest expense	(11)				(41)
Total other expenses	(164)				(97)
Income (loss) before reorganization items and income taxes	1,091				4,101
Reorganization items	24,248				24,248
Income (loss) before income tax	25,339				28,349
Income tax expense (recovery)	215				1,374
Income (loss) from operations	25,124				26,975
Net (loss) income	25,124				26,975
Predecessor | Consolidating Adjustments
REVENUE
Product sales, net	(4,477)				(8,136)
Total Revenue	(4,477)				(8,136)
EXPENSES
Cost of products sold	(2,529)				(4,605)
Total Expenses	(2,529)				(4,605)
Operating income (loss)	(1,948)				(3,531)
Other income (expense)
Income (loss) before reorganization items and income taxes	(1,948)				(3,531)
Income (loss) before income tax	(1,948)				(3,531)
Income (loss) from operations	(1,948)				(3,531)
Equity in subsidiaries	(533)				1,584
Net (loss) income	$ (2,481)				$ (1,947)